NCT07202845 Early Prediction of Neoadjuvant Chemotherapy Response in Bladder Cancer Using Quantitative Multiparametric MRI
| NCT ID | NCT07202845 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Assiut University |
| Condition | MIBC |
| Study Type | OBSERVATIONAL |
| Enrollment | 39 participants |
| Start Date | 2025-08-29 |
| Primary Completion | 2026-05-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 39 participants in total. It began in 2025-08-29 with a primary completion date of 2026-05-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Bladder cancer is a prevalent malignancy globally, with muscle-invasive disease having a five-year survival rate below 50%. Neoadjuvant chemotherapy (NAC) before radical cystectomy has shown efficacy for resectable muscle-invasive bladder cancer (MIBC). However, non-response to NAC can lead to delayed surgery and unnecessary toxicity. Magnetic resonance imaging (MRI), particularly multiparametric MRI (mpMRI) with dynamic contrast-enhanced (DCE) and diffusion-weighted imaging (DWI), offers functional and quantitative biomarkers that may predict NAC response early in treatment.
Eligibility Criteria
Inclusion Criteria: * Patients diagnosed with cT2-T4 urothelial carcinoma of the urinary bladder, according to the TNM classification (8), who give informed, written consent on participation in the study and approve all its requirements. * Planned to receive cisplatin-based NAC followed by radical cystectomy. * Willing to undergo three mpMRI scans (baseline, 24h post-initial cisplatin, and post-NAC). Exclusion Criteria: * Patients who have received pelvic radiotherapy. * Severe renal impairment * Previous open or laparoscopic pelvic surgery. * Presence of distant metastases at diagnosis. * Patients with contraindications to MRI. * Ineligibility to cisplatin
Contact & Investigator
Amr Darwish, Lecturer
PRINCIPAL INVESTIGATOR
Urology Department, Faculty of Medicine, Assiut University, Assiut, Egypt
Frequently Asked Questions
Who can join the NCT07202845 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying MIBC. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07202845 currently recruiting?
Yes, NCT07202845 is actively recruiting participants. Contact the research team at Hamza.Ahmed00099@med.aun.edu.eg for enrollment information.
Where is the NCT07202845 trial being conducted?
This trial is being conducted at Asyut, Egypt.
Who is sponsoring the NCT07202845 clinical trial?
NCT07202845 is sponsored by Assiut University. The principal investigator is Amr Darwish, Lecturer at Urology Department, Faculty of Medicine, Assiut University, Assiut, Egypt. The trial plans to enroll 39 participants.